Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis by unknown
Li et al. Breast Cancer Research 2014, 16:454
http://breast-cancer-research.com/content/16/5/454RESEARCH ARTICLE Open AccessNuclear factor of activated T cells 5 maintained
by Hotair suppression of miR-568 upregulates
S100 calcium binding protein A4 to promote
breast cancer metastasis
Jun-Tang Li1,2†, Li-Feng Wang3†, Ya-Li Zhao2†, Tao Yang1, Wei Li1, Jing Zhao3, Feng Yu2, Lei Wang3,
Yan-Ling Meng1, Ning-Ning Liu2, Xiao-Shan Zhu2, Chun-Fang Gao2, Lin-Tao Jia3* and An-Gang Yang1*Abstract
Introduction: The onset of distal metastasis, which underlies the high mortality of breast cancers, warrants
substantial studies to depict its molecular basis. Nuclear factor of activated T cells 5 (NFAT5) is upregulated in
various malignancies and is critically involved in migration and invasion of neoplastic cells. Nevertheless, the
metastasis-related events potentiated by this transcriptional factor and the mechanism responsible for NFAT5
elevation in carcinoma cells remain to be fully elucidated.
Methods: The correlation of NFAT5 with breast cancer invasiveness was investigated in vitro and clinically. The
genes transcriptionally activated by NFAT5 were probed and their roles in breast cancer progression were dissected.
The upstream regulators of NFAT5 were studied with particular attempt to explore the involvement of non-coding
RNAs, and the mechanism underlying the maintenance of NFAT5 expression was deciphered.
Results: In metastatic breast cancers, NFAT5 promotes epithelial-mesenchymal transition (EMT) and invasion of cells
by switching on the expression of the calcium binding protein S100A4, and facilitates the angiogenesis of breast
epithelial cells and thus the development of metastases by transcriptionally activating vascular endothelial growth
factor C (VEGF-C). NFAT5 is directly targeted by miR-568, which is in turn suppressed by the long non-coding RNA,
Hotair, via a documented in trans gene silencing pattern, that is recruitment of the polycomb complex (Polycomb
Repressive Complex 2; PRC2) and LSD1, and consequently methylation of histone H3K27 and demethylation of
H3K4 on the miR-568 loci.
Conclusion: This study unravels a detailed role of NFAT5 in mediating metastatic signaling, and provides broad
insights into the involvement of Hotair, in particular, by transcriptionally regulating the expression of microRNA(s),
in the metastasis of breast cancers.Introduction
Distal metastasis is the leading cause of mortality in breast
cancer patients [1]. The migration of neoplastic cells from
primary tumors to target organs occurs through a com-
plex series of steps driven by divergent molecules that* Correspondence: jialth@fmmu.edu.cn; agyang@fmmu.edu.cn
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Briefly, metastatic cells detach from the tumor mass, intra-
vasate into the blood or lymph vessels, extravasate into
surrounding tissues, and colonize appropriate organ sites
[2-4]. Numerous cytoskeleton-interacting proteins, adhe-
sion molecules, chemotactic factors, and extracellular
matrix proteins such as the matrix metalloproteinases
(MMPs) are involved in the invasion of cancer cells,
representing a common molecular machinery of me-
tastasis [5,6]. However, the upstream driver signalshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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largely uncharacterized [5,6].
Diverse transcription factor families, including the
nuclear factors of activated T cells (NFATs), have been
shown to play essential roles in regulating the expression
of metastasis-related proteins [7-9]. Accumulating evi-
dence suggests that NFAT5, which was originally identi-
fied for its involvement in osmotic cellular stress and
adaptation, plays a pivotal role in cancer cell migration
[8,10]. Nevertheless, the mechanism by which NFAT5
mediates metastasis is not fully deciphered, nor are
the signals that dictate NFAT5 expression in metastatic
breast cancers. Here, we show that in metastatic breast
cancers, NFAT5 is abundantly expressed, and the upreg-
ulated NFAT5 transcriptionally activates the calcium-
binding protein S100A4 and vascular endothelial growth
factor C (VEGF-C). Given the well-established role of
S100A4 in regulating the expression of so-called metas-
tasis executioners like MMPs, as well as the critical
involvement of VEGF-C in regulating cell adhesion, per-
meability of blood and lymph vessels, and angiogenesis
of tumors, NFAT5 is likely involved as a key player in
promoting the invasion of breast cancer cells and forma-
tion of distal metastases [11,12].
The imperative regulatory role of non-coding RNAs in
the development and progression of cancer has been
documented [13]. Of note are microRNAs (miRNAs),
which posttranscriptionally inhibit target genes, and long
non-coding RNAs (lncRNAs) such as Hotair, which is
critically involved in cancer metastasis by extensively re-
modeling the chromosomal loci of multiple metastasis-
related genes [14,15]. In addition to in cis control of the
HOX family genes, Hotair modulates the expression of a
variety of genes in trans by recruiting components of the
polycomb complex PRC2 and the LSD1/CoREST/REST
complex, thus orchestrating histone H3K27 trimethylation
and H3K4 demethylation and consequently triggering
epigenetic gene silencing [13]. While candidate Hotair-
responsive genes have been identified by a systemic
investigation based on Hotair-induced PRC2 and LSD1
occupancy, it is unclear whether miRNAs act in concert
with the lncRNAs or as targets of the lncRNAs in mediat-
ing metastasis-related signaling [14,16,17]. We found in
metastatic breast cancers that NFAT5 is a direct target of
miR-568, which is in turn suppressed by Hotair via PRC2
recruitment and subsequent chromosomal silencing of the
miR-568 gene. Thus, NFAT5 is among the candidate
mediators of Hotair-driven transcriptional activation of
metastasis-related genes in breast cancer.
Methods
Culture and transfection of breast cancer cell lines
The human breast cancer cell lines MDA-MB-231,
MDA-MB-453, MDA-MB-468, BT549, MCF-7, T47D,SKBr-3, and Bcap37 were purchased from the Cell Bank of
Shanghai Institute for Biological Sciences, Chinese Acad-
emy of Sciences. All cell lines were characterized by gene
profiling analysis by the provider, and were used fewer than
6 months after receipt. Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FBS,
and maintained at 37°C in a humidified atmosphere con-
taining 5% CO2. The miR-568 mimic, antagomiR-568, and
siRNAs were synthesized by GenePharma (Shanghai,
China). Transfection of cells was performed using
Lipofectamine 2000 reagent (Invitrogen/Life Technologies,
Carlsbad, CA, USA), according to the manufacturer’s
instructions.
Lentiviral expression of miRNA or shRNA
Short hairpin RNAs (shRNAs) were designed to target
NFAT5 using scrambled shRNA as a control. Paired
deoxyribonucleotide oligos encoding the shRNAs were syn-
thesized, annealed, and cloned into the EcoRI and NcoI sites
of the pLKO.1 vector (Addgene, Cambridge, MA, USA).
The above constructs were co-transfected into HEK293T
cells with the lentivirus packaging plasmids pCMV-VSVG
and pCMV-ΔA.9. The virus in conditioned medium was
harvested, filtered, and used for infection of breast cancer
cells. Cells were selected with puromycin (5 μg/mL) for
the generation of stable shRNA-expressing clones. For
lentiviral expression of miR-568, complementary DNA
strands corresponding to the pre-miR-568 sequence were
synthesized and cloned into the AgeI and EcoRI sites of
pGCsi-H1-CMV-GFP (GeneChem, Shanghai, China). The
recombinant or empty vector was co-transfected with the
packaging plasmids pMD2.G and psPAX2 into HEK293T
cells. The virus-containing medium was harvested,
filtered, and used for infection.
Quantitative reverse transcription (RT)-PCR
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen/Life Technologies) according to the manufac-
turer’s protocol. Reverse transcription was performed using
SuperScriptTM II Reverse Transcriptase (Invitrogen/Life
Technologies), and cDNAs were amplified and detected
using SYBR Premix Ex TaqTM (TaKaRa, Otsu, Shiga,
Japan). To quantify miRNAs, total RNA was reverse-
transcribed using the miScript Reverse Transcription Kit
(Qiagen, Hilden, Germany) and then amplified using SYBR
Premix Ex TaqTM (TaKaRa). Primers used for PCR
amplification are provided in Additional file 1: Table S1.
Western blotting
Cells were harvested at the desired times, and proteins
were extracted, separated on an SDS/PAGE gel, transferred
onto polyvinylidene fluoride membranes, and subjected to
immunoblot analyses. Blotting was performed using anti-
bodies targeting NFAT5 (Abcam, Cambridge, UK), S100A4,
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α-catenin (Santa Cruz, Dallas, TX, USA), β-catenin, Akt,
phosphorylated Akt, ERK, phosphorylated ERK (all from
Cell Signaling Technology, Danvers, MA, USA), and
β-actin (Sigma-Aldrich, St. Louis, MO, USA).
ELISA assay
VEGF-C protein in culture medium or patient peripheral
blood samples was measured using a human VEGF-C
ELISA kit (Boster, Wuhan, China). VEGF-C concentra-
tion expressed as pg/mL was calibrated against a highly
purified recombinant human VEGF-C. Briefly, 1 mL of
medium was centrifuged at 12,000 r/minute for 5 minutes
at 4°C, and 200 μL of supernatant was used in the ELISA
according to the manufacturer’s instructions. The optical
absorbance of the samples was measured at 490 nm using
a microplate reader (Bio-Rad). A serial dilution of human
recombinant VEGF-C was included in each assay to
obtain a standard curve from which the sample values of
VEGF-C were extrapolated.
Luciferase reporter assay
The 3′UTR of wild-type NFAT5 and a variant contain-
ing mutations in the putative miR-568 binding sites were
inserted downstream of the firefly luciferase gene in the
pGL3 vector (Promega, Madison, WI, USA). HEK293 cells
were co-transfected with reporter constructs, an internal
control vector (pGL4.73), and a synthetic miR-568 mimic.
At 48 h after transfection, luciferase activity was assayed
using the Dual-Luciferase Reporter Assay System (Promega)
and a luminometer (Glomax 20/20, Promega), and normal-
ized to the activity of Renilla luciferase driven by a consti-
tutively expressed promoter in the phRL vector. Basal
promoter activity was measured as the fold-change relative
to the activity observed with the basic pGL3 vector alone.
Chromatin immunoprecipitation
MDA-MB-231 cells were crosslinked with formaldehyde
and harvested for chromatin immunoprecipitation (ChIP)
as described [18]. Briefly, chromatin was fragmented by
sonication, and pre-cleared chromatin was immunoprecipi-
tated overnight with monoclonal antibodies against NFAT5
(Abcam, UK), EZH2 (Millipore, Darmstadt, Germany),
LSD1 (Abcam), trimethylated histone H3K27 (Millipore),
dimethylated histone H3K4 (Abnova) or corresponding
IgG isotype control (Abcam). The enrichment of specific
DNA fragments was analyzed by PCR with primers flank-
ing the S100A4, VEGF-C or miR-568 promoter region.
Immunofluorescence and immunohistochemistry
MDA-MB-231 cells were grown on glass coverslips and
were allowed to attach for 24 h prior to staining. The
coverslips were washed, fixed in 3.7% (wt/vol) formalde-
hyde, immersed sequentially in cold methanol and coldacetone, and then allowed to air dry. The dry coverslips
were incubated with diluted antibodies against E-cadherin
or vimentin (Abnova), followed by incubation with a
Cy3- or fluorescein isothiocyanate-conjugated second-
ary antibody. The nuclei were counter-stained with
4′,6-diamidino-2-phenylindole (DAPI). The coverslips
were mounted with Aqua-mount (Lerner Laboratories,
USA) for immunofluorescent microscopy.
The strepavidin-peroxidase (SP) method was used to
detect the expression of genes of interest in clinical
breast cancer samples by immunohistochemistry. Briefly,
tissues were sectioned, treated with 3% H2O2, and then
incubated in 5% goat antiserum. Primary antibodies
against NFAT5 (Abcam), S100A4 (Abnova), E-cadherin
(Abnova) or vimentin (Abnova) were added to serial
tissue sections and incubated overnight, followed by in-
cubation with a biotin-labeled secondary antibody. SP
complex was added and then DAB-H2O2 was used for
the color reaction before microscopy.
In vitro cell migration and invasion assays
For the cell motility assay, trypsinized cells were resus-
pended in serum-free RPMI 1640 medium supplemented
with 0.1% bovine serum albumin (BSA). Cell suspensions
were seeded in the upper chamber of a transwell insert
with an 8 μm diameter (Corning, Tewksbury, MA, USA),
and complete medium was added to the lower chamber.
After incubation for 24 h, cells on top of the membrane
were displaced with a cotton swab, and cells on the bottom
of the membrane were fixed in methanol and stained with
crystal violet. Cells in three fields were counted per mem-
brane. For the invasion assay, the transwell was coated with
200 μL Matrigel at 200 μg/mL and pre-incubated with
RPMI1640 medium. Cells were seeded into the upper
chamber of the transwell (20,000 cells/insert) and RPMI
1640/BSA was added to the lower chamber. After 24 h of
incubation at 37°C, cells were fixed in methanol and stained
with crystal violet or DAPI. Cells that invaded through the
pores to the lower surface of the filter were counted under
a microscope. Three invasion chambers were used per
condition, and the total number of cells from the three fil-
ters was averaged. For the wound-healing assay, 1 × 106
cells were seeded on 6-cm plates coated with 10 μg/mL
type I collagen. Cells were incubated for 24 h, the mono-
layer was disrupted with a cell scraper (1.2 mm width), and
photographs were taken at 0 and 24 h with a phase-
contrast microscope. Experiments were carried out in
triplicate, and four fields of each condition were recorded.
In vitro tube formation assay
Human umbilical vein endothelial cells (HUVECs) were
obtained from the Institute of Biochemistry and Cell
Biology, Chinese Academy of Sciences. Cells were co-
cultured with breast cancer cells using a double-chamber
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cells (1 × 104 cells) were seeded into transwell chambers
consisting of polycarbonate membranes with 0.45-μm
pores and allowed to adhere overnight. The chambers
were then placed into the HUVEC culture and were co-
cultured for 4 to 8 days. Medium of HUVECs was removed
and the collagen gel prepared as previously described [19]
was applied to the cells. Fresh DMEM containing 3% FBS
was then added to the collagen gel and cells were incubated
at 37°C for 24 h. The reorganization of the subconfluent
monolayer HUVECs was monitored and photographed
with a phase contrast microscope (Nikon).
In vivo tumor growth and metastasis assay
Female, 5- to 7-week-old BALB/c nude mice (Institute
of Zoology, Chinese Academy of Sciences) were injected
subcutaneously into the right hind flank with 106 MDA-
MB-231 cells infected with control lentivirus or recom-
binant lentivirus expressing an NFAT5-targeting or a
scrambled shRNA (n =5 mice/group). Tumor volume was
monitored and calculated as follows:
Tumor volume ¼ Width2  Length=2:
All mice were sacrificed at 7 weeks post-inoculation,
and tumors were removed and weighed.
For the metastasis assays, MDA-MB-231 cells infected
with control lentivirus or recombinant lentivirus express-
ing an NFAT5-targeting shRNA, a scrambled shRNA, or a
miR-568 precursor were used for in vivo metastasis assays
(n =5 mice/group). Female 5- to 7-week-old BALB/c nude
mice were injected through the tail vein with 106 cells.
The mice were monitored for general health status and
evidence of morbidity related to the primary tumor or me-
tastasis. Mice were sacrificed at 7 weeks post inoculation,
and anatomized mice were examined for metastasis in the
lung or lymph nodes. Lungs and other organs with visible
tumor colonies were fixed and embedded in paraffin, and
three non-sequential serial sections per animal were ob-
tained. The sections were stained with hematoxylin/eosin
and analyzed for the presence of metastasis by light mi-
croscopy. The total number of metastases per lung section
was counted and averaged. All of the above animal experi-
ments were approved by the Committee of Laboratory
Animal Care of the Fourth Military Medical University.
Clinical sample collection
Breast cancer, normal breast tissue and venous blood
samples were collected from Xijing Hospital, Fourth
Military Medical University, China. Briefly, breast cancer
samples from 30 patients were collected immediately
after surgical resection in the Department of Vascular
and Endocrine Surgery. All patients received surgery in
2010 without prior chemotherapy or radiotherapy. Allcases were confirmed by hematoxylin/eosin staining, and
pathological analysis revealed 8 patients with invasive
lobular carcinoma and 22 with invasive ductal carcin-
oma. The diameter of the primary tumor was ≤2 cm in
11 patients and >2 cm in 19 patients. According to the
tumor, node, metastasis (TNM) classification system of
the Union for International Cancer Control (UICC), 21
and 9 cases were at stages I/II and III/IV, respectively.
Four normal breast tissue samples were obtained from
patients undergoing breast reduction surgery in the In-
stitute of Plastic Surgery, Xijing Hospital. The samples
were then subjected to qRT-PCR or immunohistochemi-
cal analysis as described above. Patient survival time was
calculated from the date of breast cancer diagnosis to
the date of death or the last follow up.
Venous blood samples from 10 healthy volunteers, 20
patients with benign breast lesions, and 36 breast cancer
patients were collected from the Department of Oncology,
Xijing Hospital. No patients received chemotherapy, radi-
ation, or hormone therapy. Twelve of the breast cancer
patients were diagnosed with lymph node metastasis. The
concentration of VEGF-C was measured by ELISA as de-
scribed above.
All sample collections were obtained with consent from
patients for participation in the study and publication of
the results, and were approved by the Ethics Committee
of the Fourth Military Medical University.
Statistical analysis
Statistical analyses were performed using SPSS version
16.0 (SPSS Inc., Chicago, USA) for Windows. Student’s
t-test was used to analyze results expressed as the mean ±
SD, the Chi-squared test was used for the evaluation of
frequencies, and the Kruskal-Wallis test was used for
comparisons of more than two independent groups. The
Pearson correlation test was used to determine the strength
of the relationships between Hotair and miR-568 expres-
sion in clinical samples. Differences were considered
significant when the P-value was less than 0.05.
Results
NFAT5 correlates with high invasiveness of breast
cancer cells
Given the documented involvement of NFATs in car-
cinogenesis and metastasis, we first analyzed in breast
cancers the expression of NFAT5, a newly defined but
evolutionarily oldest member of the family [7-9]. As
a result, abundant NFAT5 was detected exclusively in
breast cancer cell lines with high invasive potential
(Figure 1A). In an attempt to determine the role of
NFAT5 in the invasion of breast cancer cells, we si-
lenced NFAT5 using small interfering RNAs (siRNAs)
(Figure 1B). We found that knockdown of NFAT5 in
highly metastatic breast carcinoma MDA-MB-231 cells
Figure 1 Nuclear factors of activated T cells 5 (NFAT5) dictates the invasiveness of breast cancer cells. (A) qRT-PCR (upper panel) and
western blotting (lower panel) assays for NFAT5 expression in breast cancer cell lines. Relative levels compared with the normal human mammary
epithelial MCF-10A cells were plotted for qRT-PCR. (B) qRT-PCR and western blotting assays of MDA-MB-231 cells after transfection with control
(100 nM) or NFAT5-targeted siRNAs. siNFAT5-2 was used thereafter due to its high efficacy in posttranscriptionally suppressing NFAT5 expression.
(C, D) Transwell (C) and wound-healing (D) assays of cells transfected with scrambled or NFAT5-targeting siRNA. (E) MDA-MB-231 cells were
modified with lentiviruses expressing scrambled or NFAT5-targeting shRNAs, and were injected into the tail vein of nude mice (n =10). The formation
of lung metastases were monitored and representative H&E-stained lung tissues are shown. (F) qRT-PCR assay of 30 breast cancer samples (13 with
metastases) and normal mammary tissues from four women undergoing breast reduction surgery. NFAT5 levels normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) are plotted. All data are representative photographs or represent the mean ± SD of three replicates.
*P <0.05, **P <0.01. VEGF-C: vascular endothelial growth factor C.
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transwell and wound-healing assays (Figure 1C and D).
MDA-MB-231 cells modified to express NFAT5-targeting
short hairpin RNA (shRNA) were next generated. While
the formation and growth of primary xenograft tumors
were comparable (data not shown), tumors developed
from these cells showed significantly lower potential of
lung metastasis in a xenograft model than that of tumors
derived from control MDA-MB-231 cells (Figure 1E). In
addition, NFAT5 exhibited significantly high expression
in clinical breast carcinoma samples with detected metas-
tases when compared with non-metastatic malignancies
or normal breast tissues (Figure 1F). Thus, NFAT5 is in-
volved in regulating the invasiveness of breast cancer cells.NFAT5 transcriptionally activates S100A4 and VEGF-C
NFAT5 has been reported to transcriptionally activate
the cell motility and invasion regulator S100A4/metasta-
sin, which is involved in integrin α6β4 signaling [7,20].
Meanwhile, as a transcription factor initially identified
for its vital role in osmotic stress, NFAT5 may regulate the
expression of a cohort of genes that control vascular per-
meability [8,21]. Consistent with these reports, S100A4
and VEGF-C showed similar expression patterns to
NFAT5 in breast cancer cell lines with varied invasiveness
(Figure 2A and B, Figure 1A and B). In accordance with
cellular levels of NFAT5, abundant expression of S100A4
and VEGF-C were detected in highly metastatic MDA-
MB-231 cells but not MCF-7 cells which is a non-invasive
Figure 2 S100A4 and vascular endothelial growth factor C (VEGF-C) are transcriptionally activated by nuclear factors of activated
T cells 5 (NFAT5). (A) qRT-PCR assays of the indicated transcripts in breast cancer cell lines. Relative levels compared with MCF-10A cells were
plotted. (B) Western blotting analysis (left) and ELISA quantification (right) of cellular S100A4 and secreted VEGF-C, respectively, in the indicated
cell lines. (C) RT-PCR (left), western blotting (S100A4) and ELISA (secreted VEGF-C) assays for indicated gene expression. (D, E) RT-PCR (D),
western blotting and ELISA (E) assays for gene expression and after transfection of MDA-MB-231 cells with indicated siRNAs. (F) Chromatin
immunoprecipitation (ChIP) assay using the lysates of indicated breast cancer cells. All data are representative photographs or represent
the mean ± SD of three replicates. *P <0.05.
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in substantial decrease in the cellular level of S100A4 as
well as the expression and secretion of VEGF-C (Figure 2D
and E). The binding of NFAT5 to the regulatory regions of
the S100A4 and VEGF-C loci was confirmed by chromatin
immunoprecipitation (ChIP) using an NFAT5 antibody
(Figure 2F). Thus, S100A4 and VEGF-C are transcriptionally
activated by NFAT5 in metastatic breast cancer cells.
NFAT5/S100A4 promotes invasion of breast cancer cells
via epithelial-mesenchymal transition (EMT)
The involvement of S100A4 in NFAT5-mediated invasion
of breast cancer cells was next evaluated. Comparable
to NFAT5 silencing, knockdown of S100A4 impaired the
invasion of cultured breast cancer cells (Figure 3A). Theaforementioned executioners of metastasis involved in cell
adhesion, migration and matrix degradation, in particular,
CD44, RhoA, MMP2 and MMP9 were downregulated by
siRNAs targeted to NFAT5 or S100A4 (Figure 3B). EMT
is a hallmark of metastatic neoplasms, including breast can-
cers [22]. As expected, knockdown of S100A4 enhanced
mutual adhesion of cultured MDA-MB-231 cells and in-
duced a transition toward an epithelium-like morphology
(Figure 3C). Concurrent upregulation of epithelial makers,
such as E-cadherin and α-catenin, and downregulation of
mesenchymal markers, such as vimentin, β-catenin, and
Bmi1 were observed in breast cancer cells upon ablation of
NFAT5 or S100A4 (Figure 3D to F). In advanced clinical
breast cancer samples, high NFAT5 and S100A4 expression
correlated with decreased E-cadherin but elevated vimentin
Figure 3 (See legend on next page.)
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Figure 3 Nuclear factors of activated T cells 5 (NFAT5)/S100A4 expedites epithelial-mesenchymal transition (EMT) and invasion of
breast cancer cells. (A) Transwell assay for the invasiveness of cells transfected with siRNAs targeting the indicated genes. (B) qRT-PCR assays for the
expression of metastasis-related genes in MDA-MB-231 cells transfected with indicated siRNAs. Relative mRNA levels compared with untransfected
cells were plotted. NC, scrambled negative control of siS100A4. (C) Microscopy of MDA-MB-231 cells showing suppressed spreading and increased
intercellular contact upon introduction of S100A4-targeting siRNA. (D to F) Fluorescent microscopy (D), western blotting (E) and qRT-PCR (F) assays of
MDA-MB-231 cells after transfection with siRNAs targeting the indicated genes. (G) Representative photographs of immunohistochemical staining of
breast cancers in clinical stages I to IV. Relative levels compared with untransfected cells were plotted for qRT-PCR assays in (B) and (F). All data are
representative images or represent the mean ± SD of three replicates. *P <0.05.
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for S100A4 and EMT in NFAT5-mediated metastasis of
breast cancers.
NFAT5/VEGF-C signaling is involved in breast cancer
metastasis
The formation and enlargement of metastatic foci, which
usually dictate the prognosis of breast cancers, may rely
on effective angiogenesis, prompting a potential role
of sustained VEGF-C production in distal metastasisFigure 4 Vascular endothelial growth factor C (VEGF-C) is involved in
of metastatic breast cancers. (A) In vitro tube formation of human umbil
with MDA-MB-231 cells either mocked transfected or transfected with indic
samples for comparison of VEGF-C levels in healthy volunteers, patients wit
breast cancers in various stages (C), and in patients with non-metastatic an[12]. Indeed, we found that knockdown of NFAT5 or
VEGF-C in MDA-MB-231 cells disrupted the formation
of capillary-like tubes by co-cultured epithelial cells
(Figure 4A). In clinical breast cancer samples, the ex-
pression of VEGF-C was significantly associated with
breast cancer development and advanced-stage disease,
and correlated well with the incidence of metastasis
(Figure 4B to D). These results suggest that VEGF-C
downstream of NFAT5 plays an essential role in breast
cancer metastasis.nuclear factors of activated T cells 5 (NFAT5)-driven progression
ical vein endothelial cells (HUVECs) after co-culture for indicated time
ated siRNAs or miRNA mimic (×100). (B-D) ELISA using the serum
h benign lesions, and patients with breast cancers (B), in patients with
d metastatic breast cancers (D).
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We next addressed the regulation of NFAT5 in metastatic
breast cancers with particular interests in the responsible
miRNAs, which abrogate gene expression at the post-
transcriptional or translational level [17]. We searched for
potential miRNAs which may target NFAT5, and identified
miR-568 as a candidate regulator of NFAT5 (Figure 5A).
Consistent with our previous findings in T lymphocytes
[23], the expression of NFAT5 inversely correlated with
miR-568 levels in breast cancer cell lines, with significantly
lower miR-568 expression in highly invasive cell lines
(Figure 5B). Suppression of miR-568 in MCF-7 cells caused
the upregulation of NFAT5, whereas introduction of a
miR-568 mimic dose-dependently decreased NFAT5 levels
in MDA-MB-231 cells (Figure 5C). Consistently, miR-568
significantly inhibited the expression of a luciferase reporter
gene fused to a specific wild-type but not mutated 3′ UTR
of NFAT5, suggesting the direct targeting of NFAT5 by
miR-568 (Figure 5D).
The role of miR-568 in breast cancer metastasis was
next evaluated. Similar to siRNA-mediated knockdown of
NFAT5 or S100A4, miR-568 significantly decreased the
levels of metastasis executioners (Figure 5E). Transfection
with miR-568 significantly suppressed the invasiveness of
MDA-MB-231 cells, while inhibition of miR-568 enhanced
the invasion of MCF-7 cells in a transwell assay (Figure 5F).
These results are consistent with the observation that intro-
duction of miR-568 into MDA-MB-231 cells suppressed a
mesenchymal phenotype and concurrently improved
epithelial marker expression in these cells (Figure 5G).
MDA-MB-231 cells were next infected with a control or
pre-miR-568-expressing recombinant lentivirus, and
were implanted subcutaneously in nude mice to allow
for tumor development. Compared with the tumors de-
rived from control cells, primary tumors that ectopically
expressed miR-568 showed decreased invasion and infil-
tration of peripheral tissues (Figure 5H). Significantly
lower frequency of lung metastasis was detected in
xenograft tumor models with miR-568-overexpressing
cells than in tumors from control breast cancer cells
(Figure 5H). Clinically, miR-568 expression was much
lower in metastatic breast cancers than in non-metastatic
breast cancers cells or normal breast tissues (Figure 5I).
These data suggest an essential role for miR-568 in sup-
pressing distal metastasis probably by targeting NFAT5 in
breast cancers.
Hotair suppresses miR-568 to maintain NFAT5 expression
in metastatic breast cancers
The lncRNA Hotair is an oncogenic RNA that is well
known to be involved in the metastasis of various can-
cers [14]. We found that Hotair overexpression corre-
lates with a high invasive capacity in breast cancer celllines, while only modest expression of Hotair was de-
tected in breast cancer cell lines with lower invasiveness
(Figure 6A). Inhibition of Hotair by small interfering
RNA (siRNA) dramatically impaired the invasiveness of
breast cancer cells in a Matrigel assay (Figure 6B). The
expression of Hotair was examined in clinical breast
cancer samples (metastatic or non-metastatic) and para-
neoplastic tissues. When grouped according to Hotair
levels, patients with low Hotair expression showed signifi-
cantly longer survival than those with high Hotair levels,
suggesting that Hotair may be an independent prognostic
factor of breast cancer (Figure 6C). These results are in
agreement with the well-characterized pro-metastatic role
of Hotair in cancer progression [14].
Hotair has been shown to negatively regulate a cohort
of metastasis-suppressive genes via epigenetic modifica-
tions [13-15]. We next tested whether Hotair plays a regu-
latory role on miR-568 to potentiate metastasis in breast
cancers. Indeed, a strong correlation between Hotair and
miR-568 levels was observed in clinical breast cancers
(Figure 6D). In addition, miR-568 was substantially ele-
vated in response to knockdown of Hotair in metastatic
breast cancer cells (Figure 6E). Given that Hotair recruits
the PRC2 complex and LSD1, which are responsible for
histone H3K27 methylation and H3K4 demethylation in
target genomic loci, respectively [13], we silenced LSD1
and the PRC2 component EZH2 in breast cancer cells.
Significant upregulation of miR-568 was observed in
MDA-MB-231 cells in which either EZH2 or LSD1 was
silenced, and inhibition of Hotair, EZH2, and LSD1 syner-
gized to restore the expression of miR-568 (Figure 6E).
The transcriptional start site (TSS) of the miR-568 gene
was defined in the Ensembl database and the Eukaryotic
Promoter Database (EPD) (Additional file 2: Figure S1A).
This is consistent with a PolII promoter prediction 500 to
1000 bp upstream of the TSS by the UCSC Genome
Browser (ENCODE), which also supports a high frequency
of histone H3K27 methylation in this chromosomal region
(Additional file 2: Figure S1B). Accordingly, we confirmed
by ChIP the involvement of EZH2 and LSD1 binding, and
consequently the histone H3K27 methylation and H3K4
demethylation in miR-568 suppression by Hotair in MDA-
MB-231 cells (Figure 6F). Therefore, Hotair suppresses
miR-568 via a previously established epigenetic mechanism
involving recruitment of the PRC2 complex and histone
H3K27 methylation in metastatic breast cancer.
Discussion
Breast cancer metastasis is synergistically controlled by
autonomous signaling within cancer cells and molecular
signals originating from non-tumor cells within the
changing microenvironment [4,6]. In principle, cells in the
primary tumor sense stringent conditions, such as nutrient
deficiency, undergo intracellular signaling resulting in an
Figure 5 miR-568 targets nuclear factors of activated T cells 5 (NFAT5) to regulate metastasis of breast cancers. (A) Predicted binding
sites of miR-568 on the 3′ UTR of NFAT5 mRNA. (B) qRT-PCR assay of breast cancer cell lines. Relative levels compared with GAPDH (for NFAT5)
and U6 (for miR-568) were plotted. (C) Cells were transfected with miR-568 mimics, antagomiR-568, or scrambled control, followed by RT-PCR and
western blot analysis. (D) Luciferase activity measured 24 h after co-transfection of HEK293 cells with miR-568 mimics and a pGL3 construct
containing wild-type or mutant NFAT5 3′UTR regions encompassing the three predicted binding sites of miR-568. Data were normalized to
cells co-transfected with scrambled miRNA and pGL3 vector. (E) qRT-PCR assays of MDA-MB-231 cells after transfection with indicated siRNAs.
Relative levels compared with untransfected cells were plotted. (F) Transwell assays of cells transfected with the mimics or inhibitor of miR-568
or respective control. (G) Western blotting using the lysates of MDA-MB-231 cells transfected with control or miR-568 mimics. (H) H&E staining
of primary tumors and the lung (left), and recorded incidence of lung metastases (right) by xenograft tumors derived from MDA-MB-231 cells
modified with control (vector) or pre-miR-568-expressing recombinant lentiviruses. Arrows show the tumor boundary with black arrows
indicating an invasive interface between the tumor and normal tissues. (I) qRT-PCR assay of clinically normal mammary tissues and breast
cancer samples in Figure 1F. miR-568 levels normalized to U6 are plotted. All data are representative photographs or represent the mean ± SD
of three replicates. *P <0.05.
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migration for ectopic survival [4,5]. The canonical mo-
lecular machinery involved in the multi-step process of
metastasis has been identified; however, it remains largelyelusive how these metastasis executioners are regulated by
intracellular signaling pathways controlled in response to
a diverse set of stimuli [5,6]. Here, we found that the tran-
scriptional factor plays a key role in metastasis of breast
Figure 6 Hotair epigenetically silences miR-568 in metastatic breast cancers. (A) qRT-PCR assays of Hotair expression in breast cancer cell
lines. Relative levels compared with MCF-10A cells were plotted. (B) qRT-PCR (left) and transwell (right) assays of MDA-MB-231 cells following
transfection with the indicated siRNAs. Relative levels compared with mock-transfected cells were plotted. (C) Clinical breast cancer samples
were divided into Hotair-low and -high groups (left), and the probablities of survival were plotted based on a review of in-patient records and a
follow-up study (right). (D) Pearson correlation analysis of the relative expression levels of Hotair (normalized to glyceraldehyde-3-phosphate
dehydrogenase, GAPDH) and miR-568 (normalized to U6) determined using qRT-PCR in 29 human breast cancer tissue samples. (E) qRT-PCR assay
of MDA-MB-231 cells transfected with siRNAs targeting the indicated genes. (F) ChIPs were performed using the indicated antibodies, followed
by amplification of the 5′ regulatory region of miR-568. All data are representative photographs or represent the mean ± SD of three replicates.
*P <0.05, **P <0.01 compared with all other groups.
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cells by transcriptional activating of S100A4 and probably
initiating angiogenesis of metastases via elevated secretion
of VEGF-C. Non-coding RNAs are critically involved in
the regulation of NFAT5 in that miR-568, which directly
targets and suppresses NFAT5, was epigenetically silenced
by the lncRNA Hotair.
The osmosensitive transcription factor NFAT5, also
known as tonicity-responsive enhancer-binding protein
(TonEBP), has been shown to participate in various
physiological and pathological processes, particularly in-
nate immunity and hypertension [24,25]. In cancer pro-
gression, NFAT5 acts downstream of integrin signaling
to promote invasiveness through unknown mechanisms
[7,20]. NFAT5 mediates integrin α6β4 signaling and
induces the expression of the calcium-binding protein
S100A4/metastasin to regulate breast cancer invasion
[20,26]. Consistent with these findings, we demonstrated
that S100A4 and VEGF-C are direct targets of NFAT5 in
highly invasive breast cancer cells. As a well-documented
key player in metastasis, S100A4 is implicated in the regu-
lation of a long list of genes acting at different stages of
metastasis, based on its ability to interact with myosin,p53, and cytoskeletal proteins, as well as its ability to de-
grade extracellular matrix proteins [11]. In addition,
VEGF-C enhances the permeability of vessels and induces
angiogenesis and lymphangiogenesis, which expedite the
local invasion, propogation, and colonization of neoplastic
cells, making it a widely applicable indicator of pre-
metastatic tumors [12]. While little is known about the
mechanism through which S100A4 and VEGF-C may col-
laboratively promote metastasis, they exhibit coordinated
expression in tumors, which is consistent with our find-
ings that both are upregulated in metastatic breast cancers
as target genes of NFAT5 [27].
Non-coding RNAs such as miRNAs and lnc RNAs
have emerged as key mediators of signals underlying the
malignant phenotype [14,17]. Located on chromosome
3, the biological role of miR-568 has not been fully
studied, which is in contrast to the numerous studies of
miRNAs in carcinogenesis [17,28]. The rare data avail-
able show that miR-568 correlates with the occurrence
of diabetes. MiR-568 is also a circulating miRNA specific-
ally produced by breast cancer cells [29,30]. Conversely,
we demonstrated here that intracellular miR-568 is down-
regulated in metastatic breast cancer cells by Hotair. It is
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in the ability of metastatic or localized breast tumors to
secrete specific miRNAs, including miR-568, into extracel-
lular compartments via exosomes or other vesicles. This
putative mechanism, in addition to Hotair-triggered tran-
scriptional repression, may further reduce cellular miR-
568 in invasive breast cancer cells.
The lncRNA Hotair is well documented in promoting
the metastasis of various malignancies and altering gene
expression profiles by recruitment of PRC2 components
and subsequent chromosomal gene silencing via coordi-
nated histone H3K27 methylation and H3K4 demethyla-
tion [13]. Consistent with these reports, we found that
Hotair impairs the expression of miR-568, a metastasis-
suppressive miRNA, through the aforementioned epigen-
etic mechanism [13]. While there are so far very few
miRNAs defined as targets of Hotair, our findings are in
agreement with a previous report showing the localization
of potential Hotair-responsive chromosomal regions by a
genome-wide PRC2 occupancy analysis [14]. Although it
is not known whether other metastasis-related miRNAs
are suppressed by Hotair, or how Hotair is dramatically
upregulated in metastatic breast cancer cells, our study
suggests a novel pattern of metastatic cell signaling, in
which Hotair represses a tumor suppressor miRNA and
thereby maintains high levels of key transcription factors
and their target gene products involved in metastasis.
The occurrence and progression of breast cancer is
etiologically attributed to aberrant steroid hormone and
human epidermal growth factor receptor (HER) signal-
ing, and breast cancers are thereby clinically classified by
the expression of estrogen receptors (ER), progesterone
receptors (PR), and HER2 [31-33]. Whereas therapeutics
targeting these markers have been developed and have
benefited a large population of patients, triple-negative
breast cancers usually represent a more aggressive patho-
logical type with a poor prognosis, suggesting the critical
involvement of pro-survival and pro-metastasis signaling
pathways other than ER/PR and HER2 pathways [34-36].
In this regard, whether Hotair accumulation results from
aberrant upstream signaling is unknown, nor is whether
and how miR-568 or NFAT5 may be controlled by alterna-
tive signaling, for example, the well-defined pathways in-
volved in mammary malignancy [14]. The high expression
of lncRNA Hotair is independent of known clinical risk
factors, for example, tumor stage and HER2 or hor-
mone receptor status [14]. As a evolutionarily con-
served lncRNA, which is also involved in maintenance
of chromatin structure in normal cells, Hotair might
become abundant in stochastic clones that conse-
quently gain survival and migration advantages over
other cells and potentiate distal metastasis, as proposed
previously for the well-documented cancer-initiating cells
[36]. Although this hypothesis is consistent with theobservation that Hotair signaling promotes EMT, a
characteristic of cancer stem cells, further evidence is
needed to confirm that Hotair is a driver of de novo
carcinogenesis and is indispensable for the develop-
ment of metastatic loci [36,37].
Conclusion
NFAT5 promotes breast cancer progression by transcrip-
tionally activating S100A4 and VEGF-C, whereas the
redundant NFAT5 is maintained by Hotair-elicited epi-
genetic silencing of miR-568. Our finding that Hotair
signals through miRNA(s) and key transcriptional factor(s)
to affect the expression of metastatic genes provides novel
insights into molecular mechanisms of metastasis involving
non-coding RNAs, and thus has implications for the
development of novel therapeutic approaches targeting
metastatic breast cancers.
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database (EPD). (B) ENCODE annotation of the miR-568 gene in various
cell lines showing characterized histone modifications including H3K27
trimethylation upstream of the transcriptional start site.
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